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Abstract
Cancer of the reproductive tract is an important source of morbidity and mortality
among women worldwide. Factors affecting endometrial cancer and endometrial
hyperplasia are known to be similar. Endometrial hyperplasia is abnormal prolifera‐
tion of the glands and the stroma resulting in architectural and cytological modifica‐
tions. Due to hormonal changes, this condition is most common among women who
are nearing the menopause or have reached the menopause. Antioxidant system has
a role in preventing cancer initiation and promotion. Since the carcinogenesis occurs
in several stages, it is likely that the antioxidant defense depends on the type of cell
and tissue. The objective of this study was to investigate whether antioxidant enzymes
activities and lipid hydroperoxides concentration in patients with endometrial
hyperplasia are influenced by the changes in sex hormones level (estradiol, proges‐
terone, FSH, and LH) during the menstrual cycle and in postmenopause. The material
we used consisted of blood and endometrial tissue specimens of women diagnosed
with endometrial hyperplasia simplex. Patients were divided in groups depending
on the phase of the menstrual cycle: follicular phase, luteal phase and postmenopause.
The activities of antioxidant enzymes and the lipid hydroperoxides level were
compared among the phases to test the differences and a linear regression model was
used to evaluate the associations between hormone levels and antioxidant/oxidant
variables. In the blood of examined patients, we observed a phase-related changes of
LOOH concentrations. Significant negative correlation between FSH concentration
and GR activity (r= -0.42, p<0.05) and significant positive correlation between LH and
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LOOH concentrations (r= 0.038, p<0.05) was found. In hyperplasia simplex tissue we
recorded significant phase-related changes of LOOH level as well as of AO enzyme
activities. SOD and CAT had similar activity pattern, which was higher in luteal phase
and in postmenopause, compared to follicular phase (p<0.05). GPx and GR activities
did not show any statistical difference. Also, negative correlation between progester‐
one and GR activity (r=-0.036, p<0.05) was observed. Hormonal influence on AO
system is of importance in gynecological diseases etiology since they may promote
cell proliferation but are also used in conservative therapy, especially for hyperplasia
simplex. However, the role of ROS production as a risk factor for endometrial
hyperplasia still needs to be clarified as well as the role of AO status in response to
gonadotropins and sex steroids.
Keywords: antioxidant enzymes, lipid hydroperoxides, gonadotropins, estradiol,
progesterone, endometrial hyperplasia
1. Introduction
1.1. Endometrium
The uterus (womb) is a pelvic organ with reproductive function, i.e., maintenance of preg‐
nancy. The lower, narrow part, which builds on top of the vaginal opening, was marked as
cervix, and the broader, upper part, as corpus. The corpus consists of two types of tissue. The
smooth-muscular outer layer (myometrium) has the function of expanding during pregnancy,
and it follows the development of the fetus. The inner layer (endometrium) is subjected to a
series of so-called cyclic monthly changes known as the menstrual cycle. The endometrium
consists of an outer layer, glandular epithelium, below which is an internal part, stroma. This
tissue is hormonally regulated by the steroid hormones estrogens (Es) and progestogens (Ps).
2. Gonadotropins and steroid hormones in the reproductive period
The reproductive axis consists of the hypothalamus, pituitary, and ovaries. The gonadotropin-
releasing hormone (GnRH) acts on the anterior pituitary by regulating the synthesis and
storage of gonadotropins, follicle-stimulating hormone (FSH), and luteinizing hormone (LH).
GnRH also regulates the movement of gonadotropins from the reserve pool to a readily
released point and their secretion. This action requires pulsatile GnRH release [1]. The secretion
of FSH and LH takes place in a coordinated manner so as to regulate the growth of ovarian
follicles, ovulation, and the maintenance of the corpus luteum and requires constant pulsatile
release of LHRH from the hypothalamus [2]. Both estrogens and progestins help regulate the
release of gonadotropins, acting through both the hypothalamus and anterior pituitary. High/
low levels of either progestins or a combination of progestins and estrogens, as well as the
Basic Principles and Clinical Significance of Oxidative Stress244
length of exposure to these hormones, inhibit/stimulate the release of GnRH, FSH, and LH
from the anterior pituitary – a negative/positive feedback control, respectively [3].
In the reproductive age of women, 17β-estradiol (E2) is a major circulating estrogen that is
produced by the granulosa cells of the ovary prior to ovulation and by corpus luteum following
ovulation. Almost 95 % of circulating Es in premenopausal women consists of 17β-estradiol
and the remaining 5 % originates from the peripheral conversion of the estrone (E1) to estradiol
[4]. Although a small amount of estrone, the second most important estrogen, is secreted
directly from the ovaries and adrenal glands, its main quantity derives from conversion of
androstenedione in adipose tissue [5]. The estrogenic potency of estrone is lesser than estradiol,
and both, E2 and E1, are biologically equivalent with subtle structural differences and
metabolized by the same pathways. Once a woman has reached menopause and ovaries lose
their function, estrone becomes a predominant form of estrogen [6]. Studies have shown the
trend to higher mortality rate from coronary heart disease in women with lower estrone level,
while patients with higher estrone level had lower body weight, less frequent hypertension
and diabetes mellitus, and also a lower triglyceride level [7].
During normal ovulatory cycle, the level of E2 varies individually within the range defined
for the follicular phase, mid-cycle, and luteal phase. Most of E2 in the circulation is bound to
sex hormone-binding globulin (SHBG) and to a lesser extent, to other serum proteins, such as
albumin. Only a very small fraction of this hormone is free and is located in the conjugated
form [8,9].
During a normal menstrual cycle, E2 secretion is biphasic, and the highest concentration is
recorded just prior to ovulation. This growth affects the pituitary gland secretion of FSH and
LH by a positive feedback. After ovulation, E2 level rapidly decreases and luteal cells, by their
activities, cause mild, subsequent rise and a plateau of E2 during the luteal phase [2]. During
pregnancy, the level of E2 in serum increases to much higher values than recorded in the
preovulatory peak, and it is maintained during pregnancy [10].
Progesterone (P)  belongs  to  a  group of  steroid hormones  called progestogens,  and it  is
secreted by the corpus luteum in the ovary during the second half of the menstrual cycle.
During pregnancy, the high levels of progesterone are provided by the secretion of placenta.
Contrary  to  stimulating,  proliferative  effect  of  estradiol,  progesterone  induces  secretory
activity of the endometrium and has the role of accepting a fertilized egg and beginning
pregnancy. In the circulation, progesterone is bound to the corticosteroid-binding globu‐
lin and albumin [2,11]. During normal ovulatory cycle, the increase of serum levels of P
induces an increase of LH concentration and together with E2, regulates in this way the
preovulatory  peak  of  gonadotropins  [12].  In  vivo  studies  in  humans  suggest  that  P
stimulates its own production during the periovulatory and middle luteal period through
self-priming [13]. Besides steroids, the ovary secretes peptide hormones (the inhibins) under
gonadotropin control.  The inhibins  belong to  transforming growth factors  and have the
ability  to  inhibit  gonadotropin  (FSH)  secretion  and may also  play  an  important  role  in
ovarian carcinogenesis [14].  The concentrations of inhibin A and inhibin B in circulation
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fluctuate during normal menstrual cycle.  During the follicular phase,  inhibin B is  domi‐
nant, and during the luteal phase, inhibin A dominates [15].
3. Gonadotropins and steroid hormones in menopause
The transition from the reproductive period to the menopause is a gradual process that takes
place over many years and is referred to as perimenopause. It starts with the first symptoms
of changes in the cyclic occurrence of menstruation and/or bleeding, which may be accompa‐
nied by physical and psychological symptoms and ends with the last menstruation. In terms
of morphology, this phase is characterized by a sudden drop in the number of primordial
follicles in the ovaries, as well as extreme fluctuations in hormone levels [16], so that the
frequency of normal ovulatory cycles decreases [2].
It has been shown that some women experience an increase in serum FSH concentrations
before the age of 40, especially during the mid-follicular and early luteal phase [17]. Similar
increase of FSH was also detected through regular cycles, although there were no clinical
manifestations of approaching menopause [18].
Generally, a significant increase in the concentration of FSH is observed approximately 5 years
before the onset of menopause and it is positively correlated with age [19,20]. With the onset
of menopause, there is an additional increase in FSH levels in serum for about six months, and
the peak concentration is detected 3–4 years after menopause. After this period, a slight decline
in serum FSH was detected. However, compared with fertile women, levels of gonadotropins
remained at elevated levels even 10 years after menopause [19]. Besides FSH, the LH concen‐
tration also changes during this period. It has been shown that serum LH increases slightly
during 4–5 years of perimenopause in women who still regularly cycled [17]. During the first
six months from the onset of menopause, there is an increase in serum concentrations of LH,
and the highest level is recorded during the first year of menopause. Over the next 8 years,
there is a continuous fall, but as in the case of FSH, the LH level remained elevated compared
with fertile period [19]. These data represent the results which should not be generalized and
considered as absolute parameters that apply to the period of perimenopause and menopause,
since clear markers still have to be identified. In addition, they cannot be reliably interpreted
since ovulatory (potentially fertile) cycles can normally take place immediately after the
detection of postmenopausal levels of FSH. Both estradiol and inhibin are important regulators
of the negative feedback loop of circulating FSH [21-23].
As a consequence of declined follicular function during menopause, the concentration of Es
in circulation also decreases. The level of estradiol in the serum of postmenopausal women is
less than 15 pg/ml, and the level of estrone is about 30 pg/ml, so that the ratio E1/E2 is 2:1 [11,
24]. The main source of E1, which is the principal form of the postmenopausal estrogen, derives
from androstenedione in peripheral adipose tissue and liver [2]. In this period, 95 % of the total
synthesis of androstenedione occurs in the adrenal glands and only 5 % in the ovaries [25,26].
Increased conversion of androstenedione to estrone is proportional to the increase of body
weight, and it consequently increases the amount of estrogen in the bloodstream [2,26]. The
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main source of E2 in postmenopausal women originates from the peripheral conversion of E1.
During and after menopause, the concentration of E1 decreases as well as the concentration of
E2, so that both forms of estrogen are strongly correlated [27,28]. The concentration of estrone
sulfate, which is a metabolite of those estrogens, shows a similar trend of decline in menopausal
women. Although it does not belong to the active Es, it can be activated by hydrolysis of the
sulfate group [27]. Since premenopause leads to inadequate luteal function or anovulation,
progesterone is also lowered in the serum. The level of P is further reduced during the aging
process, so it is very low in postmenopausal women [19]. Statistically, approximately 2 % to 3
% of women will develop uterine cancer during lifetime. About 97 % of all uterine cancers
originate from endometrial glands and represent endometrial carcinomas [29]. Endometrial
carcinoma is the fourth common cancer after breast, bowel, and lung carcinoma [30].
4. Endometrial hyperplasia
Endometrial  proliferation is a normal part of the menstrual cycle that occurs during the
follicular/estrogen phase of  the cycle  [31].  If  the endometrium is  exposed to  continuous
endogenous or exogenous estrogen in the absence of progesterone, simple proliferation can
advance  to  endometrial  hyperplasia,  which  is  the  most  common  precursor  of  endome‐
trioid adenocarcinoma. Generally, endometrial hyperplasia is the abnormal proliferation of
the glands and the stroma characterized by the presence of architectural and cytological
changes [32].
5. Classification and histology
As an attempt to correlate morphological features with clinical outcome, the World Health
Organization (WHO) classified endometrial hyperplasia:
Nonatypical hyperplasias (typical)
Simple hyperplasia without atypia
Complex hyperplasia without atypia (syn. adenomatous hyperplasia without atypia)
Atypical hyperplasias
Simple atypical hyperplasia
Complex atypical hyperplasia (syn. atypical adenomatous hyperplasia)
Table 1. WHO classification of endometrial hyperplasia [33]
The normal proliferative endometrium is characterized by no crowding of glands within the
stroma. Morphological features of all endometrial hyperplasia forms include an increase in
the gland-stroma ratio, irregularities in gland shape, and variation in gland size. Regardless
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of the presence of atypia, simple and complex forms of hyperplasia are distinguished by
architectural alterations characterized by glandular complexity and the amount of stroma
separating the glands [34]. Hyperplasia generally involves much of the whole endometrium,
but sometimes it may be present as a localized lesion and might be associated within an
endometrial polyp. Most endometrial hyperplasias are estrogen driven and related to type 1
endometrial carcinoma, the endometrioid endometrial adenocarcinoma [35].
Simple hyperplasia, formerly cystic or mild hyperplasia, is a proliferative lesion with minimal
glandular complexity and crowding. Histologically, glands are of irregular size from small to
those with cystic appearance and shape, separated by abundant stroma. The glandular
architectural changes are characterized by varying degrees of irregular branching. Cytologi‐
cally, the glandular epithelium resembles to proliferative endometrium. It is considered as the
least significant form which is not commonly associated with progression to endometrial
carcinoma [36].
Complex hyperplasia, previously adenomatous hyperplasia or moderate hyperplasia, represents
a proliferative lesion with severe glandular complexity and more densely crowded glands.
The glands can vary in size and may demonstrate increased structural complexity. Usually,
the glands are closely packed, frequently appearing almost back to back and with gland-stroma
ratio of more than 2:1 [37,38]. As the severity of hyperplasia increases, the glands become more
crowded and more structurally transformed. The complex hyperplasia is considered as the
true intraepithelial neoplastic process. Occasionally, this form of hyperplasia may be found
coexisting with areas of endometrial carcinoma [39]. Endometrial hyperplasia is further
classified based on the presence of cytologic atypia and disordered maturation. Cytologic
atypia refers to enlarged epithelial cells that are hyperchromatic with prominent nucleoli, an
increased nuclear-to-cytoplasmic ratio, and loss of cellular polarity. Cytologic atypia is the
most important prognostic factor for progression to endometrial carcinoma [40].
Thus, the WHO classification also includes lesions termed simple atypical hyperplasia and complex
atypical hyperplasia. Simple atypical hyperplasia is rare, so the term atypical hyperplasia is
widely used to refer to all women with simple or complex atypical hyperplasia. The glands in
atypical hyperplasia are very closely packed, and endometrial stroma might be seen, separat‐
ing them [41]. Less than 2 % of hyperplasias without atypia progress to carcinoma, and the
mean duration of progression takes almost 10 years. Atypical hyperplasia progresses to
carcinoma in 23 % of cases over a mean duration of 4 years [42].
6. Endometrial intraepithelial neoplasia system
There is a discussion to replace the WHO classification of type 1 endometrial carcinoma
precursors with the endometrial intraepithelial neoplasia classification system. This system
was proposed in 2000 by an international group of gynecologic pathologists, and it defines
two classes of endometrial changes, endometrial hyperplasia (EH) and endometrial intraepi‐
thelial neoplasia (EIN) [43]. In this classification, endometrial hyperplasia refers to changes
observed with anovulation or other etiologies of prolonged estrogen exposure. Morphologi‐
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cally, EH varies from proliferative endometrium with a few cysts to endometria with many
dilated glands. This type is also known as cystic glandular hyperplasia, mild hyperplasia, or
simple hyperplasia [44]. The term EIN represents monoclonal endometrial preinvasive
glandular proliferation as the immediate precursor of endometrial type 1 adenocarcinoma. In
EIN, the proliferation of endometrial glands exceeds the stroma (gland/stroma >1) [45]. EIN
categories do not correspond directly to the WHO system of classification. Most simple and
some complex hyperplasias fall into EH category and many complex hyperplasias with or
without atypia are in the EIN category.
7. Epidemiology and risk factors
A well-documented study regarding the epidemiology of endometrial hyperplasia included
women aged 18 to 90 over the 18-year period. The diagnosis was mostly made in women aged
50–54 years and rarely was found in women under the age of 30. The incidence of simple and
complex hyperplasia was 142 and 213 per 100,000 women-years, respectively. The rate of
atypical hyperplasia was highest in older women aged 60–64 years, and it was 56 per 100,000
women-years. This rate seems to correlate with age of peak incidence for endometrial cancer
[46,47]. Age-specific cancer incidence was demonstrated for the pancreas, bladder, stomach,
lung, prostate, ovary, colorectal, and uterine endometrium. One explanation for increased
cancer incidence with age is the latency period required for damage to occur and cancer to
develop, including the time necessary for accumulation of carcinogen-induced genetic
mutations like in oncogenes and tumor suppressor genes but also as a maladaptive response
to replicative senescence due to telomere shortening. Also, a deterioration of the innate and
the adaptive immune response with aging, referred to as immunosenescence, must be
considered [48].
Symptoms  of  endometrial  hyperplasia  include  heavy  or  prolonged  menstrual  periods,
intermenstrual  bleeding,  and  prolonged  amenorrhea.  Postmenopausal  women  with
hyperplasia may experience vaginal bleeding or spotting. However, only minority of women
with  abnormal  uterine  bleeding  (AUB)  are  subsequently  diagnosed  with  endometrial
hyperplasia [49].
The risk factors for endometrial hyperplasia are the same as for endometrial carcinoma. Most
of them include exposure of endometrium to continuous estrogen unopposed by progestin.
Unopposed estrogen may be of various sources like early menarche (beginning menstruation
before age 12), hormone replacement therapy (HRT) with exogenous estrogen, late menopause
(after 52 years of age), estrogen-secreting tumor (some breast cancer types), and nulliparity or
low parity. Medical conditions such as diabetes mellitus, polycystic ovary syndrome, or
thyroid diseases also increase the risk for hyperplasia and cancer of the uterus. Endometrial
hyperplasia is also more likely to occur in women with personal history of breast, colorectal,
or ovarian cancer and in women of white race. Endometrial cancer and hyperplasia are more
common in Caucasian women, while uterine sarcoma is more common in African American
women [50,51].
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8. Molecular pathogenesis of endometrial hyperplasia and cancer
Although the findings suggest that there are certain molecular characteristics which distin‐
guish types and degrees of endometrial cancer, the molecular mechanisms that underlie the
endometrial carcinogenesis are still unclear. Cell changes can begin with genetic aberrations
and continue with uncontrolled growth stimulated by tumor promoters.
9. Hormone receptors and growth factors
Endometrial tissue is the target tissue for steroid hormones produced by ovaries. Both
epithelium and stroma contain receptors for Es and Ps, and ovarian steroids have a funda‐
mental role in the regulation of growth and differentiation of endometrial cells [2]. It seems
this influence is partly preserved in well-differentiated tumors of the lower grade, as suggested
by data which showed that these tumors are frequently receptor positive than the advanced
tumors [52]. Growth factors are, among other influences, regulated by steroid hormones, and
they are involved in a paracrine and autocrine regulation of endometrial proliferation. The
most often mentioned are the epidermal growth factor (EGF) and transforming growth factor-
α (TGF-α). Both factors are single-chain peptides that exert their effect through the EGF
receptor. They were shown to be expressed in normal endometrial tissue [53] and to stimulate
growth of cultured endometrial cancer cells [54]. In addition to these two factors, it is consid‐
ered that the transforming growth factor-β (TGF-β) is also involved in the carcinogenesis. This
factor is expressed in normal human endometrium and certain endometrial cancer cell lines.
In some of these cell lines, like RL95-2, SPEC-2, and KLE, the TGF-β inhibits their growth [55].
Among the other growth factors which affect endometrial carcinogenesis, the basic fibroblast
growth factor (bFGF) and insulin-like growth factor I (IGF-I) should also be mentioned [56].
10. Activation of oncogenes
The most frequently altered oncogenes in endometrial cancer are the point-mutational
activation of K-ras. Point mutations of K-ras were found in approximately 10–30 % of endo‐
metrial cancers [57]. Also, K-ras mutations have been identified in endometrial hyperplasia
and more frequently in complex atypical hyperplasia, suggesting that K-ras mutations may be
an early event in endometrial carcinogenesis [58].
In addition to this oncogene, the amplification and overexpressed HER-2/neu (c-erb B-2) was
found in about 10–20 % of sporadic endometrial carcinoma cases [59-61]. HER-2/neu gene
encodes a membrane receptor protein which is structurally similar to the receptor for epider‐
mal growth factor (EGF-R). In some endometrial carcinomas, the overexpression of oncogenes
Myb, Fos, Myc, and fms, as well as their correlation with advanced stages of carcinogenesis
and poor prognosis of the outcome of survival, was recorded [57, 62]. Results of some
endometrial carcinoma studies detected the overexpression of oncogenes Myb, Fos, Myc, and
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fms, as well as their correlation with advanced stages of carcinogenesis and poor prognosis of
the outcome of survival [57, 62].
11. Inactivation of tumor suppressor genes
Until now, it is observed that mutations in PTEN (phosphatase and tenzin homologue deletion
on chromosome 10) tumor suppressor gene, also known as MMAC1 and TEP1, are detected
in approximately 50 % of endometrial cancers [63], as well as in 20 % of endometrial hyper‐
plasias, suggesting that these mutations occur relatively early in pathogenesis of this cancer
type [64, 65]. PTEN is a dual-specificity protein phosphatase which dephosphorylates tyro‐
sine-, serine- and threonine-phosphorylated proteins. Acting as lipid phosphatase, which is
critical for its tumor suppressor function, it removes the phosphate in the D3 position of the
inositol ring from phosphatidylinositol 3,4,5-trisphosphate; phosphatidylinositol 3,4-diphos‐
phate; phosphatidylinositol 3-phosphate; and inositol 1,3,4,5-tetrakisphosphate. PTEN is
crucial in the control of PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoi‐
nositides and thereby modulating cell cycle progression and cell survival [66, 67]. There is a
wide spectrum of PTEN mutations in endometrial cancer, which occur in exons 3, 4, 5, 7, and
8 and targeting the phosphatase domain and regions that control the stability and localization
of proteins. The consequence of these mutations is reduced or completely absent expression
of PTEN [68]. It was shown that progesterone treatment of cultured endometrial stromal cells
induces an increase in PTEN levels, while estradiol induces the PTEN phosphorylation. This
indicates an outstanding role of PTEN in the development and/or progression of endometrial
cancer [69]. Although loss of PTEN function was implicated in the pathogenesis of many
different tumors [70], it is believed that the altered expression of PTEN can be a diagnostic
marker for the early precancerous conditions of the endometrium [43].
Mutations of the p53 tumor suppressor gene have been found in approximately 10–20 % of all
endometrial cancers, with the greatest frequency in the high-grade tumors. Approximately 50
% of grade III tumors type 1 and the rare tumors of type 2 contain mutations in p53, but they
have not been reliably detected within the tumor of grade I or hyperplasia [68, 71, 72], so it is
considered that they occur in the late stages of endometrial carcinogenesis [56, 68]. The partial
role of the p53 in the cell cycle regulation is mediated through the transcriptional activation of
other genes, such as p21, followed by inhibition of the cyclin-dependent kinases [73]. Thus,
inactivation of p21 could potentially lead to tumor progression. Studies have shown that in
approximately 15–40 % of endometrial cancer cases, a loss of p21 gene expression can be
detected [74-76]. In addition to p53 and p21, the alterations of p16INK4a (CDKN2A) tumor
suppressor gene were also observed. This gene encodes the p16 protein that specifically binds
to CDK4 cyclin-dependent kinases, thereby inhibiting the catalytic activity of the CDK4-cyclin
D complexes. Until now, it is observed that methylation, mutations, and deletions of p16INK4a
gene are rare, and they were detected in approximately 2–6 % of endometrial cancer cases [56,
77], while the loss of expression was found in 20–70 % of cases [78-80].
Endothelins (ETs), ET-1, ET-2, and ET-3, are potent vasoconstricting peptides involved in the
pathophysiology of many human malignancies by activating G protein-coupled receptor
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(GPCR) subtypes, ETA and ETB [81]. Expression of ET-1 was detected in normal human
endometrium and in endometrial adenocarcinoma. Also, ETAR and ETBR expression was
decreased in endometrial cancer tissue compared with that of normal endometrium [82].The
ET-1-ETRA axis is frequently dysfunctional in numerous types of carcinomas and contributes
to the promotion of cell growth and migration [83].
12. Microsatellite instability
In addition to mutations of the PTEN gene, microsatellite instability (MSI) is often detected in
type 1 of endometrial cancer. MSI was first demonstrated in patients with hereditary nonpo‐
lyposis colorectal carcinoma (HNPCC), in which endometrial cancer is often an associated
phenomenon. Additional studies have shown that MSI is detected in approximately 25 % of
sporadic cases of endometrial cancer [84] or by other studies in 9–45 % of cases [56]. Unlike
hereditary forms of nonpolyposis colorectal carcinoma, where subjects with this type of cancer
carry mutations of one of the DNA mismatch repair genes, hMLH1, hMSH2, and hMSH6 [85,
86], promoter hypermethylation of the gene hMLH1 represents the predominant cause of MSI
only in sporadic cases [87]. There are also data on the hypermethylation of this gene promoter
in hyperplasia and in the absence of cancer, which suggests that inactivation of mismatch
repair genes precedes the formation of MSI [88].
13. Reactive oxygen species
Oxygen may be a source of reactive oxygen species (ROS) due to its incomplete reduction
mostly by the oxidoreductase complex I and III of the mitochondrial respiratory chain [89],
forming the superoxide anion radical (O2 •-). ROS molecules are characterized by a higher
reactivity than oxygen in its ground state. The ROS include free radicals (a term that refers to
molecules with one unpaired electron in the outer orbital), like superoxide anion radical (O2
•-), hydroxyl radical (•OH), peroxyl radical (ROO• ), as well as reactive nonradical molecules
such as singlet oxygen (1O2), peroxynitrite (ONOO-), or hydrogen peroxide (H2O2). Their half-
life varies from a few nanoseconds for the most reactive molecules up to a few seconds or hours
for stable radicals [90].
There are a few major sources of O2 •- in the cell: the respiratory chain in mitochondria,
endoplasmic reticulum cytochromes (cytochrome P-450-dependent oxygenase, NADPH-
cytochrome P-450 reductase), as well as the oxidase contained in the cell cytoplasm and
membranes (NADPH oxidase of polymorphonuclear leucocytes, macrophages, and endothe‐
lial cells) [91, 92]. The resulting O2 •- may be converted to H2O2 by spontaneous dismutation,
as well as by the enzyme superoxide dismutase (SOD). In addition, the H2O2 may originate
from the monoamine oxidase activity [93] or from the beta-oxidation of fatty acids in peroxi‐
somes [94]. Its reduction is carried out by the enzyme catalase (CAT) and glutathione peroxi‐
dase (GPx), which can be considered as the main way of detoxification. H2O2 may also be
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reduced by the neutrophil myeloperoxidase which catalyzes the conversion of H2O2 and Cl-
to hypochlorous acid (HOCl) and in the presence of transition metals (Fe2+ or Cu+), producing
•OH [95]. The hydroxyl radical is a highly reactive oxidant that reacts almost instantaneously
with the surrounding molecules abstracting the hydrogen atom (RH). The resulting free radical
(R•) is more stable and therefore has usually longer half-life compared to the •OH [96]. Peroxyl
radicals have a relatively long half-life, and they are formed in the process of lipid peroxidation,
which begins with removal of the hydrogen atom of polyunsaturated fatty acids [97]. Lipid
peroxidation in cell membranes can significantly damage their function due to the formation
of irreversible disturbance of fluidity and elasticity, which can lead to impairment of cellular
homeostasis.
ROS are constantly produced in the body as a result of normal metabolic processes, but there
is also a significant influence of external factors. Many chemical and biological agents which
are prooxidants under certain conditions can lead to increased production of free radicals. If
their production exceeds the capacity of the antioxidant defense, the oxidative stress occurs
[96]. ROS can react with any molecules in the cell, thus causing considerable damage which
results in cellular dysfunction. These processes are increasingly studied today in the frame‐
work of the mechanisms of etiopathogenesis of various diseases. Also, their role in cell
signaling, proliferation, differentiation, and programmed cell death – apoptosis – is intensively
examined.
14. Antioxidant System (AOS)
The term antioxidant refers to a substance that, when present in small amounts compared with
the substrate to be oxidized, inhibits or prevents its oxidation. The antioxidant system can be
divided into two categories: nonenzymatic antioxidants, which include various compounds
of low molecular weight (vitamin E, vitamin C, carotenoids, polyphenols, ubiquinone, and
glutathione), and the AO enzyme system [98].
15. Nonenzymatic antioxidants
Vitamin E (tocopherol-OH, vitamin E) is a generic name for a group of compounds known as
the tocopherols and tocotrienols, and it includes all forms which exhibit biological activity of
natural vitamin E (d-alpha-tocopherol) [98]. Vitamin C (ascorbic acid) is the most important
hydrophilic antioxidant. Their main function is to prevent peroxidation of lipids in the
membrane and, consequently, cell damage. The carotenoids are the vitamin A, which also
possess antioxidant properties. Beta-carotene is one of the most studied forms, and its
antioxidant function is based on its attribute to quench the singlet oxygen and remove free
radicals, thus protecting the cell membrane lipids from oxidative degradation. Polyphenols
are a group of compounds with antioxidant capacity to prevent formation of ROS production
through inhibition of the enzyme, as well as trace elements, involved in their formation [99].
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Ubiquinone prevents lipid peroxidation in liposomes, lipid emulsions, phospholipids, and
LDL particles [100]. Glutathione (GSH) is a tripeptide consisting of L-glutamine, L-cysteine,
and L-glycine. In addition to its role as a substrate of GSH redox cycles, it also removes the
hydroxyl radicals and singlet oxygen and maintains the enzymes and other cellular compo‐
nents in a reduced state [98].
16. Antioxidant enzymes
In mammals, three types of SODs have been identified, depending on the cellular localization
and prosthetic groups. In the cytoplasm, the predominant form is copper-zinc-superoxide
dismutase (CuZnSOD, SOD1), which represents a stable dimeric protein with molecular mass
of 32 kDa. It contains copper and zinc in its active site. Copper is considered necessary for the
catalytic activity of this enzyme, whereas zinc contributes to its stability [101]. CuZnSOD is
also located in the extracellular matrix, and this form is known as the extracellular superoxide
dismutase (EC-SOD, SOD3). This form of CuZnSOD is a tetrameric protein with molecular
mass of 135 kDa, and it possesses a heparin-binding domain that affects its extracellular
distribution [102]. Manganese superoxide dismutase (MnSOD SOD2) is a tetramer enzyme
with molecular weight of 88 kDa, containing manganese atom in the active sites and it is located
in the mitochondria.
CAT is homo-tetramer enzyme with molecular weight of 240 kDa, with each subunit contain‐
ing the heme prosthetic group and also the attached NADPH that protects the enzyme from
oxidative damage. CAT has a function to decompose H2O2 to O2 and H2O [103].
GPx family can be divided into two groups: selenium-independent peroxidase presented
glutathione S-transferase (GST) and selenium-dependent peroxidases (GPx).
Glutathione S-transferase belongs to the so-called phase II detoxifying enzymes that are
involved in conjugation reactions of a wide range of electrophilic xenobiotics (including
carcinogens and mutagens). Several selenoprotein glutathione peroxidases are present in
human tissues, cell GPx (GPx-1, CGP-x), gastrointestinal GPx (GPx-2, giGPx), plasma (extrac‐
ellular) GPx (GPx-3, eGPx), and phospholipid hydroperoxide GPx (GPx-4, PHGPx) and GPx-6,
which is only expressed in the epithelium of the olfactory system [104]. With the exception of
PHGPx which is a monomer (19 kDa), other forms of GPx are composed of four identical
subunits of a molecular weight of 19–25 kDa. Each subunit in its active site contains a seleno‐
cysteine (CysSe). The enzyme uses a reduced GSH as a source of reducing equivalents (elec‐
trons) to regenerate CysSe to the reduced state [105]. Glutathione reductase (GR) is an enzyme
that catalyzes the reduction of oxidized glutathione GSSG to GSH and it is essential for the
GSH redox cycle [106].
17. Oxidative stress and cell signaling
Because of their high reactivity, elevated ROS concentrations represent a great danger for
biomolecules. At physiological concentrations, these molecules are often necessary for normal
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functioning of cells as second messengers in the transduction of the cell signaling [107]. They
can be activated in such a way as to prevent or potentiate the cell death. Many signaling
pathways in the cell can be activated in both directions (cell survival or apoptosis), which
depends on the type and duration of oxidative stress or cell types. Also, some of these pathways
can affect the activation or suppression of other signaling pathways in the cell.
It is difficult to determine which type of ROS activates signaling pathways, because of their
extremely rapid conversion to other forms or due to the conversion of acid conjugates or
complexes with transition metals [108]. It is believed that H2O2 is highly suitable as a secondary
messenger because it does not randomly react with all of the molecules like other forms of
ROS, but tends to oxidize the -SH group of cysteine (Cys), which is then reduced by GSH [109].
In this way, by redox cycling of Cys, many transcription factors are regulated, such as
activating protein 1 (AP-1) [110], nuclear factor NF-IL6 [111], and proteins important in cell
signaling and cancerogenesis: protein kinase C (PKC), Ca2+-ATPase, collagenases, and SRC
tyrosine kinase [108]. It is known that ROS are critical molecules in regulation not only of the
AP-1 but also AP-2 [112] and of nuclear factor NF-kappaB [113] transcription families, which
have a decisive role in cell proliferation, differentiation, and morphogenesis.
Other processes induced by hydrogen peroxide included activation of the stress-activated
protein kinase/c-Jun N-terminal kinases (SAPK/JNK), the increased c-Jun phosphorylation,
activation of caspase 3 (CPP32), and decomposition of poly(ADP-ribose) polymerase (PARP),
which are associated with the apoptosis process [114]. Besides regulating the activity of cell
proteins, H2O2 also induces the expression of many genes [115]. In addition, these molecules
are responsible for the disruption of cell signaling and regular patterns of gene expression
[116], which can lead to a number of pathological processes including carcinogenesis. The
process of carcinogenesis is complex and consists of a series of changes at the cellular and
molecular levels and in at least three stages: initiation, promotion, and malignant conversion,
i.e., progression [117].
18. AO antioxidant status and carcinogenesis
In relation to carcinogenesis, it is known that the AO system has a role in preventing its
occurrence and promotion. The studies AO status in tumor tissues have not yet yielded results
that could lead to general conclusions about AO defense in tumor tissues. Since the carcino‐
genesis occurs in several stages, it is likely that the antioxidant defense depends on the type
of cell and tissue [118]. Mammalian cells and tissues differ significantly in the generation of
ROS. They also vary in antioxidant activity, induction capability, and cell repair capacities
which altogether results in a different susceptibility of mammalian tissues for tumor induction
[119-121].
Our earlier studies indicated a significant role of oxidative-induced injury in the breast
carcinogenesis, particularly during the later stages of aging [122]. It was also observed that
chemotherapy and radiotherapy promote further oxidative shift, which potentiates already
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existing chronic oxidative stress linked to breast cancer [123]. It is believed that the high
antioxidant capacity protects DNA from oxidative damage and mutagenesis but also can
protect the cells in the stage of initiation of increased oxidative toxicity, thus favoring their
clonal expansion and tumor progression [124]. It has long been known that oxidizing agents
may be cytotoxic, although under certain circumstances, can promote cell growth and facilitate
the clonal expansion of the initiated cells in carcinogenesis [125].
19. AO enzymes in gynecologic disorders
Some previous studies have shown that compared to healthy people, women with benign and
malignant changes in the genital tract have increased level of lipid peroxidation and altered
activity of AO enzymes in peripheral blood and tissue. Chiou and Hu [126] have detected that
the activity of SOD in plasma and erythrocytes of patients with cervicitis and uterine myoma
was lower compared to that of healthy women. At the same time, patients with cervicitis had
an increased level of CAT and GPx activity, while their activity in patients with uterine fibroids
(leiomyoma) was reduced. Similar results regarding the activities of SOD, CAT, and GPx in
erythrocytes of patients with cervicitis were obtained by Manoharan et al. [127]. These authors
also found that the activity of these enzymes was lower in patients with cervical cancer.
Research of Kolanjiappan et al. [128] and Manoharan et al. [127] showed that the level of lipid
peroxidation increased and the concentration of the antioxidant GSH, vitamin E, and CAT
decreased in erythrocytes of patients with cervical cancer. These patients had altered activity
of Na+K+-ATPase in erythrocytes compared to healthy persons. Our previous results showed
that AO status in blood of gynecological patients varies with diagnosis and the enzyme type.
Generally, both reduction in antioxidants and elevation of lipid peroxidation were observed.
Lipid hydroperoxide level was negatively correlated to SOD and GPx activities and concur‐
rently positively correlated with CAT activity. In addition, the lipid hydroperoxides/gluta‐
thione peroxidase ratio increased, according to the type of uterine disorder [129-131]. The
perturbation of antioxidant status was more pronounced in blood of patients with hyperplastic
and adenocarcinoma lesions compared to those with benign uterine changes such as polypus
and myoma. Our results of AO status in endometrial tissue showed significant decrease of
SOD activity in women with hyperplasia and adenocarcinoma. In both types of hyperplasia,
activities of GPx and GR were increased to 60 % and 100 % on average, while in adenocarci‐
noma patients, only GR activity was elevated to 100 %. CAT activity was significantly
decreased in adenocarcinoma patients (47 %). Lipid hydroperoxides level was negatively
correlated to SOD and CAT activities and positively correlated to GPx and GR activities [132].
Since association of different clinical risk factors and various types of gynecologic pathologies
is still not fully known as well as their influence on AO status, in our latest study, we evaluated
the influence of diagnostic categories, age, and reproductive factors on AO status in blood of
gynecological patients [133].The obtained results showed that reproductive and other factors
may be associated, at least partially, with AO capacity and ability to defend against the
oxidative damage in gynecological patients.
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The AO status and hormone influence were studied during the menstrual cycle and postme‐
nopause in healthy women and those with gynecologic disorders. The SOD was found to have
a role in maintaining luteal cell integrity and steroidogenic capacity in fertile women [134]. An
increase in the GPx activity was observed during the menstrual cycle, from the late follicular
to the early luteal phase. The rise in GPx activity is related to increased ovarian production of
estrogen that occurs in that particular period of menstrual cycle [135]. Decrease in GPx activity
has been noted in the endometrium and blood in late-menopausal women [136]. Menopause
is accompanied by hormone imbalance. A significant fall of the estrogen serum level with rise
of follicle-stimulating hormone (FSH) has been recorded in postmenopausal women compared
to premenopausal women [137]. Hormone replacement therapy (HRT) shows protective
antioxidant role by reduction of lipid peroxide (LOOH) serum levels [138]. It is also found that
HRT positively correlates with SOD activity in postmenopausal women [139].
We have shown that AO enzyme activity and lipid hydroperoxide level in patients with
endometrial polyps are influenced by the changes in sex hormones during the menstrual cycle
and in menopause [140]. In this study, we aimed to examine the AO status in menstrual cycle
and postmenopause of women with endometrial hyperplasia simplex as well as the relation‐
ship between sex hormones and AO parameters.
20. Methods
Subjects. The material used in this study consisted of 35 blood and tissue specimens of women
admitted to the Department of Gynecology and Obstetrics for gynecological evaluation within
routine checkups or for abnormal uterine bleeding (prolonged menstrual bleeding and
postmenopausal bleeding). On the basis of diagnosis and histological examination, subjects
were diagnosed with hyperplasia simplex endometrii, and the specimens were taken after
obtaining the informed consent. The study was conducted prospectively and it was approved
by the Human Studies Ethics Committee of the Clinical Center. The protocol was consistent
with the World Medical Association Declaration of Helsinki (Ethical Principles for Medical
Research Involving Human Subjects). None of them had undergone hormone therapy or any
other medical treatment in the last six months. Patients were divided as follows: 10 in the
proliferative (follicular phase, F) (age, 40–52 years; median 46 years), 15 in the secretory (luteal
phase, L) (age, 27–53 years; median 44 years), and 10 in the postmenopause (PM) (age, 47–60
years; median 53 years).
Samples. Samples were collected and prepared for enzyme assays according to the procedures
described previously [129,131]:
Venous blood samples were collected into heparinized tubes on the same day of uterine biopsy
and aliquoted immediately. For SOD assay (OxisResearch™), blood was centrifuged at 2500
g for 5 min. Plasma was discarded and pellet was resuspended in 4 packed-cell volume of ice-
cold demineralized ultrapure water (MilliQ reagent grade water system, Millipore Corp.,
Bedford, MA, USA). After addition of ethanol/chloroform extraction reagent (62.5/37.5 vol/
vol) to remove hemoglobin interference, samples were centrifuged at 3000 g for 10 min
Antioxidant Status and Sex Hormones in Women with Simple Endometrial Hyperplasia
http://dx.doi.org/10.5772/60853
257
(Eppendorf centrifuge 5417, Eppendorf AG, Hamburg, Germany). Upper aqueous layer was
collected and kept at -70 ºC until assay.
Fresh endometrial tissue samples were washed in saline solution and homogenized in
phosphate buffer containing 0.05M KH2PO4 and 1 mM EDTA, pH 7.8 (1 g tissue per 2 ml buffer)
in a Teflon/glass homogenizer (Spindler & Hoyer, Göttingen, Germany) and frozen at -70 ºC
for 20 h in order to disrupt cell membranes. For SOD assay (OxisResearch™), thawed homo‐
genates were vortexed 1 min and centrifuged at 8600 g, for 20 min at 4 ºC (Eppendorf centrifuge
5417, Eppendorf AG, Hamburg, Germany). According to manufacturer’s recommendation,
after addition of ethanol/chloroform extraction reagent (62.5/37.5 vol/vol) to completely
remove hemoglobin interference, samples were centrifuged at 6000 g for 20 min, at 4 ºC
(Beckman centrifuge J2-21, Beckman Instruments Inc., Palo Alto, CA, USA). Upper aqueous
layer was collected and kept at -70 ºC until assay. The enzyme activities and lipid hydroper‐
oxide (LOOH) concentration were monitored spectrophotometrically (Perkin Elmer Spectro‐
photometer, Lambda 25, Perkin Elmer Instruments, Norwalk, CT,USA).
The specific enzyme activities were expressed as Units (U) or mU per milligram of total cell
protein (U or mU/mg protein), and LOOH concentration was expressed as nmol/mg protein.
Protein concentration in tissue homogenates was performed by the method of Lowry et al.
[141] and expressed as mg/ml. Plasma follicle-stimulating hormone (FSH), luteinizing
hormone (LH), estradiol (E), and progesterone (P) levels were analyzed using standard
radioimmunoassay (RIA) methods by the hormone analysis laboratory.
Enzyme Assays. Enzyme assays were performed as described previously [132]:
Assay of SOD activity. Determination of SOD activity was performed using Oxis Bioxytech®
SOD-525™ Assay (Oxis International, Inc., Portland, OR, USA). The method is based on SOD-
mediated increase of autoxidation of 5,6,6a11b-tetrahydro-3,9,10-tryhydroxybenzo[c]fluorene
in aqueous alkaline solution to yield a chromophore with maximum absorbance at 525 nm.
The SOD activity is determined from the ratio of the autoxidation rates in the presence (Vs)
and in the absence (Vc) of SOD. One SOD-525 activity unit is defined as the activity that doubles
the autoxidation rate of the control blank.
Assay of CAT activity. CAT activity was determined by the method of Beutler [142].The reaction
is based on the rate of H2O2 degradation by catalase contained in the examined samples. The
reaction was performed in an incubation mixture containing 1 M Tris-HCl, 5 mM EDTA, pH
8.0, and monitored spectrophotometrically at 230 nm. One unit of CAT activity is defined as
1 µmol of H2O2 decomposed per minute under the assay conditions.
Assay of GPX activity. GPx activity was assessed using the Oxis Bioxytech® GPx-340™ Assay
(Oxis International, Inc., Portland, OR, USA), based on the principle that oxidized glutathione
(GSSG) produced upon reduction of an organic peroxide by GPx, is immediately recycled to
its reduced form (GSH) with concomitant oxidation of NADPH to NADP+. The oxidation of
NADPH was monitored spectrophotometrically as a decrease in absorbance at 340 nm. One
GPx-340 unit is defined as 1 µmol of NADH oxidized per minute under the assay conditions.
Assay of GR activity. Activity of GR was measured using the Oxis Bioxytech® GR-340™ Assay
(Oxis International, Inc., Portland, OR, USA). Assay is based on the oxidation of NADPH to
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NADP+ during the reduction of oxidized glutathione (GSSG), catalyzed by a limiting concen‐
tration of glutathione reductase. The oxidation of NADPH was monitored spectrophotomet‐
rically as a decrease in absorbance at 340 nm. One GR-340 unit is defined as 1 µmol of NADH
oxidized per minute under the assay conditions.
Lipid hydroperoxides. Concentration of LOOH was measured by Oxis Bioxytech® LPO-560™
Assay (Oxis International, Inc., Portland, OR, USA), which is based on the oxidation of ferrous
(Fe2+) ions to ferric (Fe3+) ions by hydroperoxides under acidic conditions. Ferric ions then bind
with the indicator dye, xylenol orange, and form a colored complex. The absorbance of the
complex was measured at 560 nm. Since hydrogen peroxide content in many biological
samples is much higher than that of other hydroperoxides, samples were pretreated with
catalase to decompose the existing H2O2 and eliminate the interference.
Statistics. Statistical analysis was carried out by the use of the Kruskal-Wallis test followed by
the Dunn’s post hoc test, which considered the unequal and small sample sizes we used in this
study. A linear regression model was used to evaluate associations between hormonal and
antioxidant variables. Before plotting the data in the regression study, the normality test on
the variables was performed, and the values of estradiol and progesterone were log trans‐
formed. The 95 % confidence intervals (CIs) for the regression lines were calculated. Two-tailed
p values are given throughout. All data were analyzed using GraphPad Prism software.
21. Results
The phase-related concentrations of gonadotropins and sex hormones are reported in Table
2. Significant changes were observed in FSH (H=12.75, p<0.01, Kruskal-Wallis), LH (H=8.98,
p<0.01, Kruskal-Wallis), and estradiol (H=7.93, p<0.05, Kruskal-Wallis) concentrations.
Follicular phase Luteal phase Postmenopause
FSH (U/L)**
Median
(Min/max)
14.30±3.51
11.50
(7.50–31.50)
13.20±2.21
10.80
(0.1–31.50)
38.88±7.88
32.15
(14.30–75.00)
LH (U/L)**
Median
(Min/max)
3.33±1.70
2.50
(0.60–9.40)
3.93±0.96
3.10
(0.60–11.20)
11.88±2.47
11.25
(1.30–24.00)
Estradiol (pg/ml)*
Median
(Min/max)
39.30±7.59
48.80
(12.60–57.20)
71.41±14.07
56.50
(10.00–208.10)
5.16±1.16
3.80
(0.70–11.40)
Progesterone (nmol/L)
Median
(Min/max)
7.40±1.09
6.30
(5.20–12.10)
8.83±2.68
5.30
(1.30–41.60)
5.16±1.16
3.80
(0.70–11.40)
Table 2. Changes in hormone levels during follicular phase, luteal phase, and in postmenopause (data are expressed as
mean ± SEM; * p<0.05, **p<0.01)
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21.1. Antioxidant parameters and correlation with sex hormones in blood
Figure 1 shows the phase-related changes of LOOH concentrations and AO enzyme activities
in the blood of examined patients. The significant change with respect to the phase was
observed in LOOH concentrations (H=5.76, p<0.05, Kruskal-Wallis). In the follicular phase, it
was significantly lower than in the postmenopause (p<0.05, Dunn test). There were no
significant changes of AO enzymes in the examined phases.
The linear regression analysis of individual hormonal variables against antioxidant parameters
in blood (Figure 2) showed a significant negative correlation between FSH concentrations and
GR activity (r=-0.42, p<0.05), as well as a significant positive correlation between LH and LOOH
concentrations (r=0.38, p<0.05). No significant correlations were found between other hor‐
mones and antioxidant variables.
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Figure 1. Changes in blood LOOH concentrations and AO enzyme activities in follicular phase (F), luteal phase (L),
and postmenopause (PM) in blood of patients with hyperplasia simplex. Data are shown as mean ± SEM. P values re‐
fer to the results of the Dunn test
21.2. Antioxidant parameters and correlation with sex hormones in hyperplasia simplex
tissue
The phase-related changes of LOOH concentrations and AO enzyme activities in hyperplasia
simplex tissue are shown in Figure 3. The LOOH concentration significantly differed with
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respect to the phase (H=7.74, p<0.05, Kruskal-Wallis), and it was significantly elevated in luteal
phase and in postmenopause, in comparison to the follicular phase (p<0.05, Dunn test).
Unlike blood, where no changes in AO enzyme activities were recorded, we found significant
phase-related changes of SOD (H=9.11, p=0.01, Kruskal-Wallis) and CAT activity H=7.60,
p<0.05, Kruskal-Wallis). Both enzymes had similar activity pattern, which was higher in luteal
phase and in postmenopause, compared to follicular phase (p<0.05, Dunn test). The phase-
related activity of GPx and GR did not show any statistical difference.
The linear regression analysis of hormone levels on the examined AO parameters in hyper‐
plasia simplex tissue showed a negative correlation between progesterone and GR activity
(Figure 4) (r=-0.36, p<0.05).
22. Discussion
Studies have shown a different AO status and sex hormone influence during menstrual cycle
and postmenopause in healthy women and those with ovarian disorders [143-146], but we
found no data regarding that relation in patients with endometrial hyperplasia simplex.
In the blood of these patients, we detected a lower level of LOOH in the F phase in comparison
to the postmenopause. In hyperplastic tissue, LOOH level was lower in the F phase than in L
phase and postmenopause. The activities of SOD and CAT were also lower in F phase when
compared to the L phase and postmenopause. There was a negative correlation between FSH/
P concentrations and GR activity in the blood and hyperplastic tissue, respectively. Positive
correlation between LH and LOOH concentrations was recorded in the blood.
Similar pattern of LOOH concentration and SOD activity in endometrium of healthy women
throughout the menstrual cycle was also observed in [134]. They found that LOOH concen‐
tration increased from early proliferative phase to mid-late proliferative phase and further
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Figure 2. Linear regression line and 95 % CI to study the relationship between log FSH and GR activity; log LH and
LOOH concentration in the blood of patients with hyperplasia simplex
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Figure 3. Changes in endometrial LOOH concentrations and AO enzyme activities in follicular phase (F), luteal phase
(L), and postmenopause (PM) in hyperplasia simplex tissue. Data are shown as mean ± SEM. P values refer to the re‐
sults of the Dunn test
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increased in the late secretory phase. The SOD activity increased from early proliferative phase
to mid-late proliferative phase, further increased in the mid-secretory phase, and then
decreased in the late secretory phase. Previous investigations of immunohistochemical
distribution of SOD in human endometrium during menstrual cycle also showed that surface
and glandular epithelia contain SOD during proliferative and secretory phases except just
prior to the menstruation [147].
The  study  of  Ota  et  al.  [148]  regarding  SOD  expression  in  endometrium  during  the
menstrual cycle of healthy fertile women and women with diagnosed endometriosis and
adenomyosis  have  shown the  phase-dependent  changes  of  SODs in  glandular  and sur‐
face epithelia in healthy women. Specifically, the expression of copper, zinc SOD was lowest
during the early and mid-proliferative phases and then gradually increased and was most
pronounced  in  the  early  and  mid-secretory  phases.  The  expression  of  manganese  SOD
reached a peak in the late secretory phase. In women with endometriosis and adenomyo‐
sis,  the  expression  of  both  SODs  was  constantly  elevated  compared  to  healthy  women
throughout  the  menstrual  cycle,  which suggested a  key role  of  superoxide  in  infertility
caused  by  endometriosis  and  adenomyosis  [148].  Our  recent  findings  in  women  with
endometrial polyp showed the opposite pattern of LOOH concentration and SOD activity
in blood and polyp tissue than in women with hyperplasia simplex. Both parameters were
higher  in  the proliferative phase compared to  the secretory phase or  postmenopause in
blood and endometrium of the examined women [140].
Regarding CAT, in [149], it was found that CAT expression in healthy women fluctuated
greatly during the menstrual cycle and the surface epithelium showed a similar pattern to that
in the glandular epithelium. The expression was the lowest during the early proliferative
phase, increased during the mid-proliferative phase, and peaked in the late secretory phase.
In patients with endometriosis, the CAT expression did not fluctuate during the cycle, but it
was consistently elevated throughout the menstrual cycle when compared to healthy women.
Likewise, in women with adenomyosis, the CAT expression did not vary during the cycle in
comparison to healthy ones, and it was significantly higher than in patients with endometriosis
[149]. In women with endometrial polyp, we found no significant change of CAT activity in
different phases [140]. In this study, however, the CAT activity in endometrium of patients
with simple hyperplasia was also similar to the healthy women.
Studies in women with gynecologic disorders indicate a different AO status, as one of the
possible factors contributing to the development of oxidative stress [150]. There are also studies
which investigated the role of oxidative stress and hormones in development of gynecologic
pathologies. For example, in [151], it was found that FSH, LH, and estrogen could induce ROS
production at different levels in ovarian epithelial carcinoma and may therefore participate in
cancer development process. FSH was found to increase cell proliferation in ovarian epithelial
carcinoma (OEC) [152], and LH may also be involved in OEC development under pathological
conditions [151].
Simple hyperplasia is the most common type of endometrial hyperplasia and the type most
likely to spontaneously regress, and it rarely progresses to endometrial cancer [42, 51, 153].
The LOOH concentrations and AO enzyme activities in this study which were similar to
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the healthy women point to the preserved cellular AO status in these patients. Endometri‐
al  hyperplasias  are  generally  considered  as  precancerous  lesions  and  are  treated  either
conservatively or surgically. The regression of hyperplastic to normal endometrium is the
main purpose of any conservative treatment. It is based on the administration of agents,
like  progestogens  [154],  which  have  an  indirect  antiestrogenic  action  and  also  a  direct
antiproliferative effect on the endometrium [155]. Also, therapeutic application of gonado‐
tropin-releasing hormone analogue (GnRHa) in women with hyperplasia was associated
with high regression rates. The regression to normal endometrium is considered to be due
to  decreased  gonadotropin  levels  as  a  result  of  pituitary  downregulation  or  to  the  de‐
creased ovarian steroidogenesis following low gonadotropin levels [156, 157]. The results
of  this  study  also  showed  that  gonadotropins  and  progesterone  influenced  oxidant/
antioxidant parameters in hyperplastic patients. Although we found no significant changes
of GR activity among the menstrual cycle phases,  FSH/P was negatively correlated with
GR activity in the blood and hyperplastic tissue, while positive correlation between LH and
LOOH  concentrations  was  recorded  in  the  blood.  Our  previous  study  in  women  with
endometrial  polyp  also  showed  the  influence  of  gonadotropins  on  AO  status.  In  these
patients, we observed a negative correlation between FSH/LH and GPx activity and also
between LH and SOD activity [140].
The role of gonadotropins in gynecological diseases in not fully clarified. In ovarian epithelial
cancer (OEC), gonadotropin theory proposes that elevated serum FSH and LH levels contrib‐
ute significantly to its development [158]. FSH generally acts through its membrane-bound
receptor which activates the intracellular signaling cascade, starting with cyclic AMP/protein
kinase A (cAMP/PKA) that is followed by phosphorylation of specific transcriptional factors,
like cAMP-response element-binding protein (CRE), or p38 MAPK, which controls other
kinase cascades. The FSH receptor can also activate extracellular signal-regulated protein
kinases (ERK-s) [159].
It was shown that synthesis of antioxidants, such as glutathione in the ovary, is regulated by
gonadotropins, but exact mechanisms are still unknown [160]. One of the mechanisms behind
FSH and antioxidants interaction is through activation of transcriptional factors, like Nrf2. The
induced Nrf2 binds to the antioxidant-response element (ARE), thus coordinately regulates
the expression of AO genes [161].
The pathogenesis of endometrial hyperplasia is still not fully understood. Prolonged estrogen
stimulation is considered as one of the factors related to the etiology. This study showed that
patients with endometrial hyperplasia simplex have similar AO status like healthy women,
and it also demonstrated the relation of hormones and prooxidant/antioxidant parameters in
this gynecologic disorder. Since simple hyperplasia may spontaneously regress, these results
point to the preserved AO capacity as a potentially important factor in the regression mecha‐
nisms. However, the role of ROS production as a risk factor for endometrial hyperplasia still
needs to be clarified as well as the role of AO status in response to gonadotropins and sex
steroids.
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